How Korea Can Avoid Pitfalls Of Over-Reliance On Out-Licensing
Citeline’s Pang Suggests Diverse Business Models For Korean Biopharma
Executive Summary
An over-reliance on out-licensing as a business model may restrict the healthy growth of South Korean biopharma firms over the longer term, a Citeline executive told a recent symposium in Seoul.
You may also be interested in...
New Korea Commission Needs Status To Function As Control Tower: Industry
A policy report by a major South Korean pharma industry association puts forward suggestions on what it will take for a new pan-government control tower to function properly.
Global Health Leaders Highlight Pandemic Preparedness
At the recent World Bio Summit in Seoul, global health leaders discussed international cooperation strategies and policies to prepare for the next pandemic, with a focus on rapid vaccine development.
Are Korean Biopharma Alliances Recovering After Gloomy Year?
Recent sizable out-licensing deals with global big pharma firms are raising hopes of a recovery in Korean biopharma alliances and also point to possible changes in deal structures towards international norms.